The Trump administration is currently considering Dr. Norman “Ned” Sharpless for the role of FDA chief. Dr. Sharpless, known for his criticism of vaccine policies promoted by Health and Human Services Secretary Robert F. Kennedy Jr., previously led the National Cancer Institute during President Trump’s first term. His tenure at the NCI and brief stint as acting FDA commissioner in 2019 have earned him praise and positioned him as a stabilizing candidate for the FDA amidst recent upheaval.
Potential Shift in Health Policy
This consideration marks a potential departure from the “Make America Healthy Again” movement, which has seen its influence diminish as the administration seeks to address perceived weaknesses in health policy. Dr. Sharpless has no direct ties to Kennedy or the MAHA movement, which has been credited with aiding Trump’s 2024 presidential victory but has since seen its influence wane.
Since leaving government service, Dr. Sharpless co-founded a venture capital fund focused on biotechnology and has been a professor at the University of North Carolina School of Medicine. He has publicly opposed recent FDA vaccine policy changes, emphasizing the importance of maintaining a regulatory model that ensures vaccine safety and availability.
Other Candidates in Consideration
In addition to Dr. Sharpless, the Trump administration is also considering Richard Pops, a pharmaceutical executive, for the FDA chief role. Pops, who is stepping down as CEO of Alkermes, is viewed favorably within the pharmaceutical industry, which has had contentious interactions with the recently ousted FDA commissioner, Marty Makary.
Acting FDA commissioner Kyle Diamantas is another candidate, though his limited experience with drug issues could hinder his chances. Diamantas has impressed officials with his efforts to promote healthier eating policies, aligning with some of the MAHA movement’s goals.
Challenges Ahead
The search for a new FDA chief is a high priority as the administration seeks to fill key vacancies within the Department of Health and Human Services. The chosen candidate will need to navigate complex political dynamics, including gaining approval from both Kennedy and Trump, as well as securing confirmation from a closely divided Senate.
Several Republican senators have expressed concerns about the FDA’s stance on the abortion pill mifepristone, which could become a significant issue for the new FDA chief. Dr. Sharpless has previously supported the FDA’s scientific decisions regarding mifepristone, which may complicate his confirmation process.
Original reporting: KRDO (Colorado Springs metro) — read the source article.
